Respiratory Syncytial Virus (RSV) Vaccine
The purpose of the study is to determine the safety and effectiveness of an investigational RSV vaccine (respiratory syncytial virus) compared to a placebo (inactive substance). Respiratory syncytial virus is a virus that can cause respiratory tract infections. It is also the most common cause of pneumonia in young children and older adults. The study will last up to 1 year and 7 months and consist of up to 4 visits to the study site and 2 phone calls. There may be additional study visits and/or phone calls if you volunteer to give extra blood samples, or if you develop a respiratory infection. While in the study, your study-related visits, study-related vaccines, lab work and procedures are provided at no charge. If you do qualify and enroll, you may be compensated for your time and travel.
Please visit our sister site to sign up for this study : www.RSVResearch.com
Male and Female
Why take part?
Participants will receive study-related doctor’s care, study medication at no cost. Compensation for study-related time and travel may be available.Millions of people lack the treatment they need to manage their conditions. As one of the largest and most recognized clinical study organisations in the world, Synexus provides a friendly relaxed environment where you have the opportunity to help others and maybe also yourself.
Who is Synexus?
Synexus is a company dedicated to conducting clinical studies, and has been investigating the effectiveness of new study drugs and treatments for more than 20 years. We provide a friendly, relaxed environment in our own clinics where you have the chance to help shape the future of health for yourself and for others.We are sure you probably have more questions about the study, and we would be happy to take the time to give you more details.
All Synexus studies are approved by an independent ethics committee.